E exceeds the higher tolerable limits. We wanted to assess the heavy metal and trace element levels in patients with chronic TE. Materials and Methods: A total of 40 subjects with chronic TE were included in the study, and 30 healthy women served as control. General and dermatological examinations were taken up in all individuals. Those patients with positive hair pull test were evaluated with the help of a trichogram. The presence of >20% telogen hair as documented by trichogram was a requirement for the study inclusion. UNICAM-929 spectrophotometry device was used for determining serum trace element and heavy metal concentrations. Results: In spite of an absence of significant differences in terms of average Zn concentration, weight, or height between patients and controls, significant differences were noted for Cd, Fe, Mg, Mn, Pb, Co, and Cu (P <0.05). Conclusion: Our results suggest that heavy metals may play a causative role in the development of chronic TE. However, contrary to previous reports, zinc did not appear to play an important etiological role, while these patients had elevated serum iron levels....
8 March 2021 in International Journal of Dermatology
Background: Vitiligo, particularly when involving the face, is associated not only with visible disfigurement but also with profound psychosocial consequences. Despite growing interest in the psychosomatic dimensions of skin diseases, the relationship between facial vitiligo and social appearance anxiety remains underexplored. Objectives: To evaluate the level of social appearance anxiety in patients with facial vitiligo and to compare it with healthy controls. Further, to examine how this anxiety correlates with broader psychological and quality-of-life parameters. In addition, we conducted secondary analyses, including subgroup comparisons based on facial lesion location, and moderation analysis using general anxiety as a moderator. Methods: A cross-sectional case–control study was conducted among 156 patients with nonsegmental facial vitiligo and 143 demographically matched healthy controls. All participants completed the Social Appearance Anxiety Scale (SAAS) and the Hospital Anxiety and Depression Scale (HADS). Patients with vitiligo additionally completed the Dermatology Life Quality Index and a visual analogue scale assessing perceived disease severity. Facial lesion regions were classified anatomically (forehead, periorbital, perioral, mandibular) for subgroup analysis. Moderation analysis was performed to examine whether general anxiety (HADS-Anxiety) moderated the relationship between lesion visibility and SAAS scores. Results: SAAS scores were markedly higher in the group with vitiligo (mean 55.2, SD 9.2) than in controls (mean 19.7, SD 8.4), with a large effect size (Cohen’s d = 4.16; P < 0.001). In patients with vitiligo, SAAS scores were significantly correlated with anxiety (r = 0.75), depression (r = 0.50), quality-of-life impairment (r = 0.41) and perceived severity (r = 0.61); all P < 0.01. Subgroup analysis revealed significantly higher SAAS scores among patients with periorbital and perioral involvement than in those with mandibular or isolated forehead lesions (P < 0.05). Moderation analysis confirmed that the strength of association between lesion location and SAAS was significantly amplified in patients with high HADS-A scores (interaction term P < 0.01). Conclusions: Facial vitiligo imposes a substantial psychological burden, characterized by elevated social appearance anxiety that extends beyond general psychopathology. Our findings suggest that specific lesion sites, particularly periorbital and perioral areas, are more psychologically distressing and that general anxiety amplifies this impact. These results underscore the need for tailored psychosocial support depending on lesion location and baseline anxiety levels.
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.
1 January 2019 in Advances in Dermatology and Allergology
Introduction Hirsutism is defined as excessive terminal hair in androgen-dependent areas in women. Adipose tissue is no longer regarded as a storage site for triglycerides or as a source of free fatty acids but is currently emerging as a key constituent of energy metabolism secreting...